Podchaser Logo
Home
143 - Diacerein 1% for Epidermolysis Bullosa; epoetin alfa biosimilar; MRI with reduced scan time; Gilenya® for pediatric relapsing MS

143 - Diacerein 1% for Epidermolysis Bullosa; epoetin alfa biosimilar; MRI with reduced scan time; Gilenya® for pediatric relapsing MS

Released Wednesday, 16th May 2018
Good episode? Give it some love!
143 - Diacerein 1% for Epidermolysis Bullosa; epoetin alfa biosimilar; MRI with reduced scan time; Gilenya® for pediatric relapsing MS

143 - Diacerein 1% for Epidermolysis Bullosa; epoetin alfa biosimilar; MRI with reduced scan time; Gilenya® for pediatric relapsing MS

143 - Diacerein 1% for Epidermolysis Bullosa; epoetin alfa biosimilar; MRI with reduced scan time; Gilenya® for pediatric relapsing MS

143 - Diacerein 1% for Epidermolysis Bullosa; epoetin alfa biosimilar; MRI with reduced scan time; Gilenya® for pediatric relapsing MS

Wednesday, 16th May 2018
Good episode? Give it some love!
Rate Episode

May 16, 2018 

Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://newfdaapprovals.com 

1:25 Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa https://www.prnewswire.com/news-releases/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-epidermolysis-bullosa-300649448.html

3:21 FDA approves first epoetin alfa biosimilar for the treatment of anemia https://www.prnewswire.com/news-releases/fda-approves-first-epoetin-alfa-biosimilar-for-the-treatment-of-anemia-300648734.html https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607703.htm

4:21 Medic Vision: new FDA-cleared MRI image enhancement technology enables reduction of scan time and increased resolution https://www.prnewswire.com/news-releases/medic-vision-new-fda-cleared-mri-image-enhancement-technology-enables-reduction-of-scan-time-and-increased-resolution-682660651.html

5:26 Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis https://www.prnewswire.com/news-releases/novartis-announces-fda-approval-of-gilenya-as-the-first-disease-modifying-therapy-for-pediatric-relapsing-multiple-sclerosis-300647266.html https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607501.htm 

Music credit: freemusicarchive.org/music/MindsEye/Yellow_Taxi/

Show More
Rate

Join Podchaser to...

  • Rate podcasts and episodes
  • Follow podcasts and creators
  • Create podcast and episode lists
  • & much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.
,

Unlock more with Podchaser Pro

  • Audience Insights
  • Contact Information
  • Demographics
  • Charts
  • Sponsor History
  • and More!
Pro Features